These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12194730)

  • 1. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living.
    Cohen CJ; Dusek A; Green J; Johns EL; Nelson E; Recny MA
    AIDS Patient Care STDS; 2002 Jul; 16(7):327-35. PubMed ID: 12194730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous injection survey: psychometric evaluation of a treatment satisfaction instrument associated with a novel HIV medication.
    Green J; Kleinman L; Ciesla G; Huang J; Wintfeld N; Revicki D
    HIV Clin Trials; 2002; 3(5):387-95. PubMed ID: 12407488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks.
    Cohen C; Hellinger J; Johnson M; Staszewski S; Wintfeld N; Patel K; Green J
    HIV Clin Trials; 2003; 4(5):347-57. PubMed ID: 14583851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen.
    Cohen CJ; Clumeck N; Molina JM; Thompson M; Patel K; Wintfeld N; Green J
    J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1140-6. PubMed ID: 15319673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
    Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
    N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
    N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
    Moltó J; Ruiz L; Valle M; Martinez-Picado J; Bonjoch A; Bravo I; Negredo E; Heilek-Sneider GM; Clotet B
    Antivir Ther; 2006; 11(1):47-51. PubMed ID: 16518959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The optimal use of enfuvirtide.
    Gallant JE
    Hopkins HIV Rep; 2003 May; 15(3):1-3. PubMed ID: 12809103
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration.
    True AL; Chiu YY; Demasi RA; Stout R; Patel I
    Pharmacotherapy; 2006 Dec; 26(12):1679-86. PubMed ID: 17125431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
    Cervia JS; Smith MA
    Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enfuvirtide (T-20): potentials and challenges.
    Foy K; Juethner SN
    J Assoc Nurses AIDS Care; 2004; 15(6):65-71. PubMed ID: 15538017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with a new fusion inhibitor: patient issues with enfuvirtide (T-20). A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.
    Glutzer E
    AIDS Read; 2003 Mar; 13(3 Suppl):S14-6. PubMed ID: 12765161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enfuvirtide access, administration, and patient education.
    Celano SA
    Hopkins HIV Rep; 2003 May; 15(3):1, 12. PubMed ID: 12809102
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-HIV agents. T-20 (enfurvirtide, Fuzeon).
    TreatmentUpdate; 2005; 17(1):5-6. PubMed ID: 17225316
    [No Abstract]   [Full Text] [Related]  

  • 16. Quality of life and tolerability after administration of enfuvirtide with a thin-walled needle: QUALITE Study.
    Shalit P; True A; Thommes JA;
    HIV Clin Trials; 2007; 8(1):24-35. PubMed ID: 17434846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1.
    Pérez-Alvarez L; Carmona R; Ocampo A; Asorey A; Miralles C; Pérez de Castro S; Pinilla M; Contreras G; Taboada JA; Nájera R
    J Med Virol; 2006 Feb; 78(2):141-7. PubMed ID: 16372284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enfuvirtide doubles chances for suppression.
    AIDS Patient Care STDS; 2004 Sep; 18(9):550. PubMed ID: 15630779
    [No Abstract]   [Full Text] [Related]  

  • 19. Patients' perception and effectiveness of a treatment containing enfuvirtide when used in HIV-infected patients without very advanced disease.
    Pulido F; Del Pozo MA; Fernández-Guerrero M; Moreno A; Oteo JA; Flores J; Pedrol E; Torres R; Padilla B; Téllez MJ; García J; González-García J;
    HIV Clin Trials; 2008; 9(2):83-90. PubMed ID: 18474493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138).
    Boulet T; Pavie J; Charreau I; Braun J; Reynes J; Morlat P; Piroth L; Spire B; Molina JM; Aboulker JP;
    HIV Clin Trials; 2010; 11(5):283-93. PubMed ID: 21126958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.